H.B. Fuller successfully issued $850 million in senior notes due in 2034, with partial redemption tied to the Advanced Medical Solutions acquisition. The company is also reviewing potential divestitur
H. B. Fuller shares rose 1.8% after Q3 fiscal 2026 earnings beat estimates with $1.52 EPS and $938.2M revenue. Driven by pricing and restructuring, the company outperformed the S&P 500 despite downwar
H.B. Fuller Company issued $850 million in senior unsecured notes to fund its acquisition of Advanced Medical Solutions Group PLC via subsidiary Bidco. This financing replaces the previously arranged
H.B. Fuller's board unanimously rejected Ancora's unsolicited $1.2–$1.4 billion bid for its Building Adhesive Solutions business, citing undervaluation. The company will conduct a market check of sele
H.B. Fuller's board rejected Ancora's unsolicited $1.4 billion offer for its Building Adhesive Solutions segment, citing undervaluation. The company will conduct a market check on other segments to re
H.B. Fuller's board unanimously rejected Ancora's unsolicited $1.2 billion to $1.4 billion offer for its Building Adhesive Solutions segment, deeming it inadequate. The company will explore divesting
H.B. Fuller priced an $850 million senior notes offering at 7.625%, intending to use proceeds to acquire Advanced Medical Solutions Group plc and refinance debt. The transaction includes a contingency
H.B. Fuller Q3 net income rose 17.9% to $79.2M, beating estimates as pricing countered raw material costs. Full-year revenue guidance stands unchanged with mid-single digit growth forecast.
H.B. Fuller reported strong Q3 2026 results with $1.52 EPS and $938.2 million revenue, exceeding Wall Street expectations. Management issued full-year adjusted EPS guidance of $4.70 to $4.85, citing c
H.B. Fuller reported Q3 earnings of $1.52 per share and revenue of $938.18 million, surpassing analyst estimates. Despite four consecutive quarters of beating EPS, the stock remains a Zacks Sell due t
H.B. Fuller reported quarterly earnings of $1.52 per share, exceeding estimates by $0.05, and updated fiscal 2026 guidance to $4.70–$4.85. Shares fell 1.2% to $50.48 despite the positive financial res
H.B. Fuller reported third-quarter earnings per share of $1.52, beating estimates by $0.05, while revenue of $938 million missed forecasts. The company issued full-year 2026 EPS guidance between $4.70
Engine Capital urges H.B. Fuller's board to consider Ancora's $1.1–$1.2 billion bid for its Building Adhesive Solutions segment. This follows shareholder concerns over the company's recent acquisition
H.B. Fuller announced shareholder approval for its acquisition of Advanced Medical Solutions Group plc, expected to close by year-end to strengthen its healthcare platform.
H.B. Fuller confirmed an unsolicited $1.1–$1.2 billion cash acquisition proposal from Ancora Holdings Group for its Building Adhesives Solutions segment. The board will evaluate the offer with advisor
H.B. Fuller reported 7,143 employees worldwide as of March 2026, down 1.2% from 2023. However, active job postings surged 49.5% year-over-year, reflecting continued hiring despite workforce contractio
H.B. Fuller amended its senior credit agreement, extending maturities to July 2031 and increasing its revolving credit facility to $800 million. The company lowered interest margins and terminated a b
H.B. Fuller reported Q2 fiscal 2026 earnings beating estimates due to strong pricing actions and restructuring savings. The company raised its full-year outlook and highlighted the proposed acquisitio
H.B. Fuller received a "Moderate Buy" consensus with a $66.40 price target after beating Q2 revenue and EPS estimates. However, its planned £715 million acquisition of Advanced Medical Solutions faces
H.B. Fuller proposed a £715 million acquisition of wound-care supplier AMS, facing criticism from activist investor Ancora Holdings who urged deleveraging. The deal aims to expand market reach and ach
H.B. Fuller Company reported Q2 2026 earnings with an EPS of $1.41, beating estimates by $0.03. Revenue reached $950.27 million, marking a 5.81% year-over-year increase exceeding projections.
H.B. Fuller reported better-than-expected Q2 earnings and raised its full-year outlook. The strong financial performance led to a positive revision of future projections for the adhesive manufacturer.
UBS raised H.B. Fuller's price target to $71 citing earnings optimism, while JPMorgan upgraded the stock to Neutral referencing valuation and the Advanced Medical Solutions deal. The company retains i
H.B. Fuller set 2030 sustainability targets including a 25% reduction in Scope 1 GHG emissions and a 75% increase in recycling rates against a 2025 baseline. The adhesive maker also aims to cut water
H.B. Fuller Senior Vice President Heather Campe received 37.2 phantom units on June 5, 2026, increasing her total equity holdings to include over 24,000 common shares and various restricted stock unit
H.B. Fuller has reportedly submitted an all-cash proposal to acquire Advanced Medical Solutions at 285 pence per share, facing a decision deadline of June 18, 2026. The move follows Advanced Medical S
H.B. Fuller is reportedly making a cash takeover offer exceeding £600 million for Advanced Medical Solutions Group (AMS). This strategic acquisition aims to expand H.B. Fuller's presence in the health
US adhesives maker H.B. Fuller launched an unsolicited takeover bid for UK medical supplier Advanced Medical Solutions, lifting shares 13.5% following failed private equity negotiations.
H.B. Fuller plans to construct an innovation center in Charlotte, NC, targeting aviation, space, and defense markets by early 2027. The facility will consolidate manufacturing and testing operations t
H.B. Fuller aims to achieve over 20% EBITDA margins by streamlining manufacturing and optimizing its portfolio despite rising raw material costs and solar demand headwinds. Analysts forecast a fair va
H.B. Fuller announced a 4.3% increase in its quarterly cash dividend to 24.5 cents per share. The payment will be made on May 14, 2026, to shareholders of record as of April 30, 2026.
H.B. Fuller posted adjusted earnings of 57 cents per share, beating consensus estimates of 55 cents, citing raw material cost savings as a key driver.
H.B. Fuller exceeded financial estimates despite a decline in sales volume. The company forecasts mild revenue and adjusted EBITDA increases for fiscal 2026.
ChemBrief